WildingJPCharpentierGHollanderP, et al.Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: A randomised trial. Int J Clin Pract2013; 67: 1267–1282.
2.
LeiterLAYoonKHAriasP, et al.Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: A randomized, double-blind, phase 3 study. Diabetes Care2015; 38: 355–364.
3.
MazidiMRezaiePGaoHK, et al.Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: A systematic review and meta-analysis of 43 randomized control trials with 22 528 patients. J Am Heart Assoc2017; 6. DOI: 10.1161/JAHA.116.004007.
4.
NealBPerkovicVMahaffeyKW, et al.CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med2017; 377: 644–657.
5.
VaduganathanMSathiyakumarVSinghA, et al.Prescriber Patterns of SGLT2i After Expansions of U.S. Food and Drug Administration Labeling. J Am Coll Cardiol2018; 72: 3370–3372.
6.
ArnoldSVInzucchiSETangF, et al.Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR Research to Practice project. Eur J Prev Cardiol2017; 15: 1637–1645.
7.
SchernthanerGGrossJLRosenstockJ, et al.Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: A 52-week randomized trial. Diabetes Care2013; 36: 2508–2515.
8.
ForstTGuthrieRGoldenbergR, et al.Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab2014; 16: 467–477.
9.
NorhammarAMellbinLCosentinoF. Diabetes: Prevalence, prognosis and management of a potent cardiovascular risk factor. Eur J Prev Cardiol2017; 24: 52–60.
10.
UsmanMSSiddiqiTJMemonMM, et al.Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis. Eur J Prev Cardiol2018; 25: 495–502.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
